Atomico

Atomico is the European venture firm most likely to be in the room when an ambitious technology founder is choosing between a top-tier US partner and a credible European-led round. Founded by Niklas Zennstrom in London, the firm has spent over a decade building a Series A and B practice that competes for the same companies as the larger US growth-stage firms, with a deliberate focus on European-headquartered or European-founder-led companies that have global ambition. For healthcare founders, Atomico’s relevance is sharpest where applied AI meets digital health, health IT, and software-defined care delivery, rather than in pure therapeutics or device-heavy verticals.

The investment thesis is centered on backing ambitious founders building category-defining technology companies, with a meaningful and growing lean into applied AI across enterprise software, consumer technology, climate, and health IT. Atomico is not a healthcare specialist, and founders should not pitch the firm as if it were one. The firm engages with healthcare when the company is fundamentally a software, data, or AI business that happens to operate in a health context, particularly where workflow, infrastructure, or platform dynamics dominate clinical specialization. Stage focus runs from Series A through Series C, with the firm building meaningful ownership at A and B and reserving capital for follow-on rounds. The European mandate is real but not exclusive; Atomico has invested in US companies where there is a European angle or where a transatlantic syndicate makes sense. For healthcare AI founders, the most productive framing is to position the company as a category-defining software platform with global ambition, and to address how the company will navigate health system fragmentation across multiple regulatory regimes.

The specific portfolio detail provided in the source is limited to the firm’s broader profile, but Atomico has been a recognized backer of high-profile European technology companies across SaaS, fintech, marketplaces, and consumer technology, with health IT and digital health representing one of several growing themes. Founders should diligence the current portfolio directly through the firm’s website rather than relying on outdated public lists, as Atomico actively rotates its public portfolio presentation around current investment priorities.

Check sizes typically run between five and twenty-five million dollars, placing Atomico firmly in the lead Series A and Series B range with capacity to anchor Series C participation. The firm prefers to lead or co-lead rounds and to take board seats, which means founders should expect a meaningful governance relationship rather than a passive financial position. Geographic flexibility is a feature; while London is the operating base, the team is comfortable across continental Europe and engages selectively with US-headquartered companies, particularly when the founder profile or expansion thesis has a European dimension. There is no published hard revenue requirement, but at Series A and B, Atomico expects credible commercial traction, customer evidence, and a clear path to category leadership.

The firm is partner-driven with a London base and a structured investment process. Founders should expect a multi-meeting diligence cycle, partner consensus on commitment, and post-investment engagement that includes board involvement, talent and operating support, and downstream introductions to other European and US investors. Atomico has built a meaningful operational platform over time, and the firm is generally well regarded for the quality of its post-investment engagement among European venture peers.

Warm introductions through existing Atomico portfolio CEOs are the most reliable path in, followed by referrals from other top-tier European or US Series A and B investors who frequently syndicate with the firm. London-based operators, repeat European founders, and well-known European angel investors are also strong referral sources. Cold inbound is read but, given the firm’s deal flow, the conversion rate is low without a specific, credible angle. A short, sharp memo that establishes category, traction, and why the company is European-headquartered or European-led will materially outperform a generic intro.

Founders should approach Atomico when the company is at Series A or beyond with credible commercial momentum, when the business is fundamentally a software, data, or applied-AI platform with a healthcare context, and when there is a genuine ambition to build a category-defining global company rather than a regional player. Atomico is not the right fit for early-stage therapeutics, hardware-heavy medical devices, or care delivery models that are fundamentally services businesses with limited software leverage. For the right healthcare AI software founder, Atomico is one of the few European firms that can credibly lead a competitive Series A or B against US peers and bring the operational platform to match.